Science Abstracts
Prasugrel: a novel platelet ADP P2Y
12 receptor antagonist. A review on its mechanism of action and clinical development
May 2012
May 2012
Authors : Dominick J Angiolillo , Siva Suryadevara , Piera Capranzano , Theodore A Bass
Affliation : University of Florida College of Medicine–Shands Jacksonville, Division of Cardiology, 655 West 8th Street, Jacksonville, FL 32209, USA ; ; dominick.angiolillo@jax.ufl.edu
DOI : 10.1517/14656566.0.0.345208
Published in : Expert Opin. Pharmacother.
Subject: Drug Evaluation
Keywords: acute coronary syndrome , antithrombotics , percutaneous coronary intervention , platelets , thienopyridines , thrombosis
Abstract
Antiplatelet therapy is the cornerstone of treatment...
Please Login to read the full article.
RELATED CONTENT
NEWS
- AstraZeneca heartened by US FDA nod to antiplatelet medicine Brilinta
- Takeda resubmits alogliptin NDAs in US as cardiovascular data become available
- ARISTOTLE: changing thinking about BMS/Pfizer's Eliquis in anticoagulation?
- Xiaflex for Dupuytren's positive in pilot using convenient multiple injections
